Eisai Co., Ltd. (TYO:4523)
Japan
· Delayed Price · Currency is JPY | Market Cap | 1.28T |
| Revenue (ttm) | 803.02B |
| Net Income (ttm) | 50.33B |
| Shares Out | 281.89M |
| EPS (ttm) | 178.19 |
| PE Ratio | 25.49 |
| Forward PE | 32.59 |
| Dividend | 160.00 (3.57%) |
| Ex-Dividend Date | Sep 29, 2025 |
| Volume | 1,224,800 |
| Average Volume | 1,465,650 |
| Open | 4,580.00 |
| Previous Close | 4,542.00 |
| Day's Range | 4,519.00 - 4,645.00 |
| 52-Week Range | 3,463.00 - 6,271.00 |
| Beta | -0.18 |
| RSI | 72.24 |
| Earnings Date | Aug 5, 2025 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Methycobal for the treatment of peripheral neur... [Read more]
Financial Performance
In 2024, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.
Financial StatementsNews
Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease
Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation
Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on Wedne...
"URECE" (Dotinurad) Launched in China as a treatment for Gout
TOKYO, July 14, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: dot...
Eisai: Leqembi Approved In EU (Rating Downgrade)
Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript
Eisai Co., Ltd. 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Eisai Co., Ltd.
Eisai GAAP EPS of ¥163.76, revenue of ¥789.4B; initiates FY outlook
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
The European Commission (EC) on Tuesday approved Eisai Co., Ltd. (OTC: ESALY) and Biogen Inc.’s (NASDAQ: BIIB) amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) , The Commission said it gran...
Biogen/ Eisai win EU approval for Alzheimer’s therapy
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.
Japanese Stocks Rise With Market Focused on U.S. Trade News
Japan's Nikkei Stock Average closed 0.3% higher at 35725.87 as gains in the heavy industry and video game shares offset the losses in pharmaceutical and utility stocks. IHI gained 5.7% and Konami rose...
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight
New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight LEQEMBI (lecanemab) has significant market p...
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug
European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November.
Eisai: Will Have No Problem Hitting Leqembi Forecasts
Q3 2025 Eisai Co Ltd Earnings Presentation Transcript
Q3 2025 Eisai Co Ltd Earnings Presentation Transcript
Eisai projects 42.5B yen global revenue for LEQEMBI in FY2024 amid pathway expansion
Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript
Eisai GAAP EPS of ¥160.14, revenue of ¥601.16B; reaffirms FY outlook
Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
STOCKHOLM , Jan. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM : BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supp...